Related by context. All words. (Click for frequent words.) 80 Cutaneous T 77 Renal Cell Carcinoma 76 Myelodysplastic Syndromes 76 Follicular Lymphoma 76 Adjuvant Treatment 76 Chronic Myeloid Leukemia 75 Advanced Renal Cell 75 Malignant Melanoma 75 Prolongs Survival 75 Relapsed Refractory 75 Soft Tissue Sarcoma 74 Severe Sepsis 74 Clinical Trial Results 74 Advanced Melanoma 74 Previously Treated 74 Gastric Cancer 74 Oral Fingolimod 73 Antitumor Activity 73 Diffuse Large B 73 Pooled Analysis 73 Metastatic Melanoma 73 Study Evaluating 73 Adjuvant Chemotherapy 73 Advanced Colorectal Cancer 73 Newly Diagnosed 73 Mouse Model 73 Cell Lymphoma 73 Patients Treated With 73 Mantle Cell Lymphoma 73 Leukemias 73 Hepatocellular Carcinoma 73 Chronic Myelogenous Leukemia 73 Hormone Refractory Prostate Cancer 72 Newly Diagnosed Multiple Myeloma 72 Metastatic Colorectal Cancer 72 Phase 2b Clinical Trial 72 Relapsing Multiple Sclerosis 72 Previously Untreated 72 Preclinical Models 72 Anti Tumor 72 Hsp# Inhibitor 72 Improves Outcomes 72 Subgroup Analysis 72 Autoimmune Disease 72 Randomized Study 72 Tyrosine Kinase Inhibitor 72 Castration Resistant Prostate Cancer 72 Meets Primary Endpoint 72 Fungal Infections 72 Improved Survival 72 Drug Candidate 72 Lung Cancer Patients 72 Renal Cancer 71 Anticancer Drugs 71 Treating Chronic 71 Complicated Skin 71 HDAC Inhibitor 71 Unresectable 71 Chronic Lymphocytic Leukemia CLL 71 Stomach Cancer 71 Improves Survival 71 Anti Tumor Activity 71 Breast Cancer Recurrence 71 Solid Tumors 71 Metastatic Prostate Cancer 71 Acute Myeloid Leukemia 71 Combination Treatment 71 Myelofibrosis 71 Epratuzumab 71 Decitabine 71 Slow Progression 71 Chronic Hepatitis C 71 Brentuximab Vedotin SGN 71 metastatic malignant 71 Multicenter Trial 71 Phase III Trial 71 Antigen Specific 70 Epidermal Growth Factor Receptor 70 Disease Progression 70 Progenitor Cells 70 Phase 2b Study 70 Hematological Malignancies 70 Insulin Resistance 70 Novel Oral 70 Lung Cancer Trial 70 Rheumatoid Arthritis Patients 70 Glioblastoma Multiforme 70 Drug Shows Promise 70 B Cell Lymphoma 70 Myeloma Patients 70 Endometrial Cancer 70 Combination REOLYSIN R 70 Relapsing Remitting Multiple Sclerosis 70 Bladder Cancer 70 Myelodysplastic Syndrome MDS 70 Inflammatory Markers 70 Relapsed Multiple Myeloma 70 Lung Cancer Survival 70 Investigational Drug 70 Long Term Efficacy 70 HCV Protease Inhibitor 70 Diabetic Nephropathy 70 Investigational Compound 70 HER2 Positive 70 Genes Predict 70 Placebo Controlled Study 70 Myelodysplastic Syndrome 70 Vitro Activity 70 Chronic Sinusitis 70 Survival Benefit 70 Clinical Outcome 70 Nilotinib 70 Autoimmune Diseases 70 Adenomas 70 Shows Promising 70 Investigational Agent 69 Receives Orphan Drug Designation 69 Ovarian Cancer Patients 69 II Clinical Trial 69 Improve Survival 69 Lung Cancer Drug 69 Prospective Randomized 69 Colorectal Cancer Patients 69 Inflammatory Disease 69 Pivotal Phase III 69 Neoadjuvant Chemotherapy 69 Bosutinib 69 Completes Patient Enrollment 69 Diabetic Patients 69 Patients Receiving 69 Idiopathic Pulmonary Fibrosis 69 Chronic Hepatitis B 69 Liver Cancer 69 Anticancer Drug 69 Investigational Treatment 69 Phase 2a Trial 69 Heart Failure Patients 69 Prostate Cancer Patients 69 HER2 Positive Breast Cancer 69 Randomized Double Blind 69 Plus Ribavirin 69 Systemic Lupus Erythematosus 69 Invasive Breast Cancer 69 Lupus Nephritis 69 Respiratory Distress 69 Bevacizumab 69 Lymphoid 69 Pulmonary Arterial Hypertension 69 Carcinoma 69 Tumor Progression 69 Antiangiogenic 69 Metastatic Renal Cell Carcinoma 69 Acute Pancreatitis 69 Gene Mutation 69 Prostate Cancer Vaccine 69 Oral Mucositis 69 Hepatocellular 69 Overactive Bladder 69 Preclinical Data 69 Node Positive 69 Sipuleucel T 69 Combo Therapy 69 Recombinant Human 69 T Cell Lymphoma 69 Phase IIb Trial 69 Malignant Glioma 69 Randomized Phase II 68 Breast Cancer Cells 68 Lung Cancers 68 Critically Ill Patients 68 Systemic Sclerosis 68 Philadelphia Chromosome Positive 68 Drug Resistant 68 Initiate Phase 68 Randomized Phase 68 Immunotherapeutic 68 Tumor Growth 68 Liver Failure 68 Atopic Dermatitis 68 Cardiotoxicity 68 Kidney Transplant Patients 68 Protein Involved 68 Phase III Trials 68 Refractory Hodgkin Lymphoma 68 Slows Progression 68 Pralatrexate 68 Relapsed Refractory Aggressive 68 Novel Inhibitor 68 Novel Mechanism 68 Prostate Cancer Treatment 68 Targeted Therapies 68 Nucleoside 68 Advanced Prostate Cancer 68 Phase IIb Clinical Trial 68 Rheumatoid Arthritis Drug 68 Trial Evaluating 68 Emerging Therapies 68 Genetic Variant 68 Adjuvant Therapy 68 Adenoma 68 Romiplostim 68 Treatment Shows Promise 68 Aflibercept 68 Initiates Clinical Trial 68 Cancer Vaccines 68 Placebo Controlled Trial 68 Phase 2a Clinical Trial 68 Kinase Inhibitor 68 Treatment Reduces 68 Renal Impairment 68 leukemia AML 68 Preclinical Study 68 Monoclonal Antibody 68 Smooth Muscle 68 Safinamide 68 Rotavirus Vaccine 68 Multiple Myeloma Patients 68 Autologous Stem Cell Transplantation 68 IND Application 68 Hedgehog Pathway Inhibitor 68 Phase III Clinical Trial 68 Elderly Patients 68 Glioma 68 ISTODAX ® 68 Orally Active 68 Brain Metastases 68 Ischemic Stroke 68 Liver Tumors 68 Genetic Disorder 68 FDA Okays 68 Autoimmune Disorders 68 Unfractionated Heparin 68 Non Invasive Treatment 68 Gene Linked 68 Treatment Resistant 68 Metastatic Breast Cancer 68 Blood Cancers 68 Newly Diagnosed Patients 68 Dendritic Cells 68 Alemtuzumab 68 Well Tolerated 68 Antiviral Therapy 68 Metastatic 68 Therapy Improves 68 Shows Efficacy 68 Cardiac Arrhythmias 68 Breast Cancer Patients 68 Naive Patients 68 Multiple Myeloma 68 Patients Treated 68 Acute Heart Failure 68 Hepatic Encephalopathy 68 Biologic Therapy 68 Acute Leukemia 68 Bronchiectasis 68 Tumor Suppressor 68 Novel Treatments 68 Cholesterol Lowering Drug 68 Peripheral Blood 68 Liver Metastases 68 Kidney Transplant Recipients 68 Successfully Completes Phase 68 Hepatitis C Virus 68 Statistically Significant 68 Prognostic Factors 67 Progressive Multifocal Leukoencephalopathy 67 Increased Mortality 67 Phase 2b Trial 67 refractory chronic lymphocytic 67 Cognitive Impairment 67 Plaque Psoriasis 67 Anthracycline 67 Squamous Cell Carcinoma 67 Interferon Alfa 67 Rectal Cancer 67 RNAi Therapeutic 67 Peginterferon 67 Tyrosine Kinase Inhibitors 67 Acute Myelogenous Leukemia 67 relapsed leukemia 67 Gaucher Disease 67 Factor Receptor 67 Sustained Efficacy 67 Granted Orphan Drug 67 Stem Cell Treatment 67 Immune Responses 67 Treatment Naive Patients 67 Hormone Receptor Positive 67 chronic eosinophilic leukemia 67 Monoclonal Antibodies 67 Hypercholesterolemia 67 Psoriasis Patients 67 Cell Transplants 67 Eculizumab 67 Randomized Phase III 67 Prognostic Significance 67 Lowers Risk 67 Nicotine Vaccine 67 Polymerase Inhibitor 67 Patient Enrollment 67 Combination Therapy 67 Aggressive Prostate Cancer 67 Intracranial Aneurysms 67 Allogeneic 67 Allergic Rhinitis 67 Generalized Anxiety Disorder 67 Effectively Treats 67 ACE Inhibitors 67 Pharmacokinetics PK 67 Non Hodgkin Lymphoma 67 Predict Breast Cancer 67 Prophylactic Treatment 67 Septic Shock 67 Breast Tumors 67 Genes Linked 67 Myeloid 67 Erectile Dysfunction Drug 67 Randomized Double blind 67 familial amyloidotic polyneuropathy FAP 67 Iron Overload 67 Hematological Cancers 67 Completes Enrollment 67 atypical Hemolytic Uremic Syndrome 67 Cytotoxicity 67 Lenalidomide 67 Monotherapy 67 Dose Finding 67 Pirfenidone 67 Drug Prevents 67 Dose Escalation Study 67 Pediatric Patients 67 Neoplasia 67 Diagnostic Criteria 67 Metastases 67 Carcinomas 67 Resistant Hypertension 67 Hepatitis B Virus 67 leukemia ALL 67 Oxidative Stress 67 Lymphomas 67 Left Ventricular 67 FDA Approves Drug 67 Metastatic Pancreatic Cancer 67 Dose Escalation 67 Pivotal Study 67 Cyclooxygenase 2 67 Anticancer Activity 67 Secondary Hyperparathyroidism 67 Shows Promise Against 67 Skeletal Muscle 67 Risk Stratification 67 Treatment Experienced 67 Etanercept 67 Renal Function 67 Nonalcoholic Fatty Liver Disease 67 Atypical Antipsychotics 67 Postmenopausal Women 67 Osteoporosis Treatment 67 Pivotal Trial 67 Demonstrates Potential 67 Ofatumumab 67 JAK Inhibitor 67 Double Blind Placebo 67 Teva Provides Update 67 Multicenter Study 67 hypereosinophilic syndrome 67 Respiratory Virus 67 Beneficial Effects 67 Sustained Reduction 67 imatinib Gleevec ® 67 Bone Metastases 67 Lymphocytic 67 Advanced Ovarian Cancer 67 Myocardial Ischemia 67 Novel Antibiotic 67 Pulmonary Hypertension 67 Pharmacokinetic Study 67 Breast Cancer Metastasis 67 Renal Cell Cancer 67 Acute Myeloid Leukemia AML 67 Transplant Patients 67 myelodysplastic myeloproliferative diseases 67 Predict Risk 67 Aurora Kinase 67 Chronic Heart Failure 67 Enlarged Prostate 67 Genes Associated 67 Proves Effective 67 Hepatitis B Vaccine 67 Single Dose 67 Benign Prostatic Hyperplasia 67 Phase IIa Clinical Trial 67 Knee Osteoarthritis 67 Neuropathic Pain 67 Multiple Myeloma MM 67 Protease Inhibitor 66 Bipolar Mania 66 Invasive Fungal Infections 66 Artery Disease 66 Golimumab 66 Glufosfamide 66 Novel Therapeutic 66 Boosts Survival 66 Therapeutic Efficacy 66 Targeted Therapy 66 gastrointestinal stromal tumor GIST 66 Drug Fails 66 Brain Tumors 66 Cell Transplant 66 Demonstrates Potent 66 Low Dose 66 Epoetin Alfa 66 Ulcerative Colitis 66 follicular Non Hodgkin 66 Sapacitabine 66 Cancer Recurrence 66 Elagolix 66 Dasatinib 66 Bortezomib 66 Cutaneous Melanoma 66 Treated Patients 66 metastatic GIST 66 Immune Mediated 66 Fibrosis 66 Hematological 66 Hodgkin lymphoma HL 66 Therapeutic Vaccine 66 Fluorouracil 66 Diabetic Foot Ulcer 66 Inhaled Corticosteroids 66 Metabolic Disorder 66 Hemodialysis Patients 66 Mouse Models 66 Present Preclinical Data 66 Romidepsin 66 Breast Cancer Treatment 66 metastatic renal cell carcinoma 66 Cell Non Hodgkin 66 Files IND 66 Drug Combo 66 Inhibits 66 Subtypes 66 Vicriviroc 66 Endothelial Cells 66 Treatment Naive 66 Disease Modifying 66 Severe Asthma 66 Pemetrexed 66 Systemic Delivery 66 Clinical Efficacy 66 Controlled Study 66 Respiratory Syncytial Virus 66 Novel Compound 66 Lupus Drug 66 JAK2 Inhibitor 66 Non Alcoholic Steatohepatitis 66 Rheumatoid Arthritis RA 66 Diabetic Neuropathy 66 Is Well Tolerated 66 Neural Stem Cells 66 Kinase Inhibitors 66 Demonstrates Significant 66 Venous Thromboembolism 66 Acute Renal Failure 66 Controlled Trial 66 Thrombotic 66 Predict Response 66 Thromboembolic 66 Treatment Regimen 66 Gout Drug 66 Antiviral Activity 66 SPRYCEL ® 66 See CLINICAL PHARMACOLOGY 66 Advanced Solid Tumors 66 Kidney Function 66 Chemotherapeutic Agents 66 NCCN Updates 66 Patient Outcomes 66 Lung Tumors 66 Cellular Immunotherapy 66 leukemia CLL 66 Kidney Failure 66 Inflammatory Diseases 66 erythematosus 66 Radical Prostatectomy 66 Initiates Phase III 66 Kidney Transplants 66 Atypical Hemolytic Uremic Syndrome 66 Phospholipase A2 66 Abiraterone Acetate 66 Protein Linked 66 myeloproliferative neoplasms 66 Chemotherapy Induced 66 Human Neural Stem 66 Appears Safe 66 Enzyme Replacement Therapy 66 Relapsed 66 IL# PE#QQR 66 dasatinib Sprycel ® 66 First Patient Dosed 66 Replacement Therapy 66 Patients Undergoing 66 Fludarabine 66 Infected Patients 66 Neoadjuvant 66 Chronic Constipation 66 Antidepressant Drug 66 Tumor Necrosis Factor 66 Psoriasis Drug 66 Acute Myeloid Leukaemia AML 66 Epstein Barr Virus 66 Acute Myocardial Infarction 66 Hypertensive Patients 66 Childhood Leukemia 66 Oral Cavity 66 Skin Lesions 66 refractory cutaneous T 66 Squamous 66 Cyclophosphamide 66 Presents Preclinical Data 66 Ozarelix 66 Androgen Deprivation Therapy 65 Submits NDA 65 Oral Cladribine 65 Stem Cell Transplants 65 Laryngeal Cancer 65 Thyroid Cancer 65 Angiogenic 65 Clostridium difficile Infection 65 Biological Therapy 65 Late Breaker 65 stage IIIB 65 gastrointestinal stromal tumors GIST 65 Short Stature 65 Therapeutic Targets 65 Perifosine KRX 65 advanced metastatic renal 65 Long Term Survival 65 Polymorphisms 65 First Patient Enrolled 65 Dialysis Patients 65 Cardiovascular Outcomes 65 Paraplatin ® 65 NDA Submission 65 Successfully Treated 65 Phase 1b Clinical Trial 65 Tumor Targeting 65 Renal Failure 65 Protease Inhibitors 65 Malignant Brain Tumor 65 Therapeutic Antibodies 65 FDA Accepts 65 Cytotoxic T 65 Community Acquired Pneumonia 65 Receptor Agonist 65 Hospital Acquired Pneumonia 65 precursor acute lymphoblastic 65 Dupuytren Contracture 65 Neovascular Age Related Macular 65 Adenocarcinoma 65 cell lymphoma CTCL 65 Breast Cancers 65 Often Misdiagnosed 65 Neuroendocrine Tumors 65 Study Shows Promise 65 Cancer Patients Treated 65 Antitumor activity 65 Growth Hormone Deficiency 65 Initiate Phase III 65 Tumor Cell 65 ara C 65 erlotinib Tarceva ® 65 Long Term Outcomes 65 Postmenopausal Osteoporosis 65 Test Detects 65 Virus Infection 65 Tanespimycin 65 Immunosuppression 65 Rheumatoid 65 Therapeutic Potential 65 Prostatic 65 metastatic colorectal 65 myelofibrosis polycythemia vera 65 Anemia Drug 65 Prostate Cancer Survival 65 Colorectal Adenomas 65 Pancreatic Cancer 65 Hepatitis C Treatment 65 Pre Cancerous 65 Statin Drugs 65 Chemoradiation 65 FDA Approvals 65 Antiplatelet Therapy 65 Initiates Clinical 65 Capecitabine 65 recurrent glioblastoma multiforme 65 Adjunctive Therapy 65 multiple myeloma MM 65 Cancer Therapies 65 Mimetics 65 antibody MAb 65 Demonstrates Efficacy 65 Pre Eclampsia 65 R lenalidomide 65 Cancer Cells 65 Urinary Incontinence 65 Adjuvant Breast Cancer 65 Clinical Trial Data 65 Systemic Lupus Erythematosus SLE 65 IND Filing 65 FOLOTYN ® 65 complement inhibitor eculizumab 65 Showed Significant 65 Anti TNF 65 Abstract Number 65 Treat Anemia 65 pan HDAC inhibitor 65 Voreloxin 65 Randomized Clinical Trials 65 Experimental Vaccine 65 nilotinib Tasigna 65 Vasculitis 65 Epilepsy Drug 65 Preclinical Efficacy 65 Interferon Alpha 65 Blood Pressure Drug 65 Paclitaxel Carboplatin 65 Protein Synthesis 65 Advanced Pancreatic Cancer 65 Genetic Predisposition 65 Pivotal Phase 65 Initiates Enrollment 65 C1 Inhibitor 65 Schizoaffective Disorder 65 Potent Inhibitor 65 Patients Suffering 65 PEGylated interferon beta 1a 65 Cocaine Addiction 65 Demonstrates Positive 65 Angioedema 65 Stent Placement 65 systemic anaplastic large 65 Arthritis Drug 65 Vaccine Shows Promise 65 Circulating Tumor Cells 65 HCV Genotype 65 Clinical Trial Evaluating 65 Fast Track Status 65 Chronic Renal Failure 65 Clofarabine 65 Mycophenolate Mofetil 65 CYT# potent vascular disrupting 65 Multicenter Randomized 65 Kit CD# positive 65 Natalizumab 65 Receptor Antagonist 65 Gene Variation 65 Ovarian Cancer Treatment 65 Liver Injury 65 Pegylated Liposomal Doxorubicin 65 Analytical Tool 65 Refractory Angina 65 Adenoviral 65 Cardiovascular Disease Risk 65 Heterozygous Familial Hypercholesterolemia 65 AA Amyloidosis 65 Tigecycline 65 Gene Variant 65 Prostate Cancers 65 Genital Herpes 65 Carotid Stenting 65 Polycythemia Vera 65 Microalbuminuria 65 GW# [003] 65 Peginterferon Alfa 2a 65 Oral Presentations 64 Treatment Naïve 64 Pegylated Interferon 64 Treatment Naïve Patients 64 Chronic Kidney 64 Azacitidine 64 Panic Disorder 64 Major Depressive Disorder 64 Crit Rev 64 cetuximab Erbitux R 64 Inflammatory Arthritis 64 Reperfusion Injury 64 Hepatitis C Genotype 64 Prolongs Life 64 accumulate preferentially 64 Malignancies 64 Randomized Controlled Trials 64 Interferon Beta 64 Tumor Response 64 Irinotecan 64 Cognitive Function 64 Hemorrhagic Stroke 64 Tasigna nilotinib 64 Study Showed 64 Trodusquemine MSI 64 Intracerebral Hemorrhage 64 chronic myeloid 64 Anthrax Toxin 64 Randomized Controlled 64 huN# DM1 64 Meta Analysis 64 Juvenile Idiopathic Arthritis 64 Chronic Inflammation 64 Receives Positive Opinion 64 Acute Decompensated Heart Failure 64 lymphoid malignancies 64 Demonstrated Significant 64 Ibritumomab Tiuxetan 64 Lung Cancer Treatment 64 Renal Anemia 64 Efficacy Trial 64 Localized Prostate Cancer 64 Dose Ranging Study 64 sunitinib Sutent ® 64 INCB# [003] 64 Ovarian Cancers 64 Omacetaxine 64 Gene Therapy Trial 64 Oncolytic Reovirus 64 Anti Angiogenesis 64 Psychiatric Disorders 64 Biomarker Study 64 Epilepsy Drugs 64 Non Hodgkin 64 essential thrombocythemia ET 64 TNF Blockers 64 Obesity Linked 64 histone deacetylase HDAC inhibitor 64 Hematologic 64 Anti Angiogenic 64 Schizophrenia Drug 64 Patient Enrolment 64 Genetic Mutation 64 Diabetic Macular Edema 64 Carotid Endarterectomy 64 Pancreatic 64 Reduces Mortality 64 Confirmatory Phase 64 Ischemic 64 Combination Clinical Trial 64 Cancer Treatments 64 Prostate Tumors 64 Chronic HCV 64 Randomized Double Blind Placebo 64 Antitumor 64 Pneumococcal Vaccine 64 Zarnestra 64 Systemic lupus erythematosus SLE 64 Gene Mutations 64 Phase Ib Clinical Trial 64 Significantly Improved 64 Viral Load 64 Radioimmunotherapy 64 Dilated Cardiomyopathy 64 Restless Legs 64 Randomised Controlled Trial 64 Immunomodulatory 64 Phase III Clinical Trials 64 Pegylated 64 Genes Identified 64 Gemzar ® 64 Genetic Variation 64 Therapeutic Antibody 64 Cloretazine ® 64 Potent Anti 64 Frontotemporal Dementia 64 Leukemia Cells 64 NICE Recommends 64 Beta Blocker 64 Recurrent Breast Cancer 64 Estrogen Receptor 64 RNAi Therapeutics 64 Granulocyte Colony Stimulating Factor 64 Sleep Disturbances 64 Boceprevir 64 Inherited Diseases 64 HCV Infection 64 Immune Cell 64 Treating Heart Failure 64 Orphan Diseases 64 Novel Therapies 64 mRCC 64 Synthetic Peptide 64 ASCO GI 64 Surgical Treatment 64 pralatrexate injection folate analogue 64 Acute Myelogenous Leukemia AML 64 Thyroid Hormone 64 Selective Inhibitor 64 Prospective Multicenter 64 Treatable 64 Hepatitis C Infection 64 PEGylated Fab fragment 64 Esophageal Cancer 64 Receptor Antagonists 64 transthyretin TTR mediated amyloidosis 64 Tiotropium 64 5 Fluorouracil 64 Cytochrome P# 64 Neuroprotective Effects 64 Initiates Phase II 64 BRAF V#E 64 Anti CD# Antibody 64 Bucindolol 64 cancer mCRC 64 EGFR HER2 64 Immunomedics Announces 64 Signaling Pathway 64 Tesamorelin 64 Vaccine Candidate 64 Endocrinol 64 Aliskiren 64 Newly Diagnosed Breast Cancer 64 Cell Proliferation 64 Osteoporosis Drug 64 Monoclonal 64 Completes Dosing 64 Chronic Pelvic Pain 64 gefitinib Iressa 64 Complete Remission 64 Anti Inflammatory Drug 64 Protein Kinase 64 HIV Infection 64 Cannabinoid 64 telomerase therapeutic 64 Fallopian Tube 64 Topical Treatment 64 Cardiovascular Events 64 Pivotal Clinical Trial 64 Cardiovascular Mortality 64 Prognostic Value 64 Gene Variants 64 ST Segment Elevation 64 Limb Ischemia 64 Acute Ischemic Stroke 64 Pulmonary Artery 64 Myoblast 64 Relapsed Refractory Multiple Myeloma 64 Non Inferiority 64 Tumor Suppressor Gene 64 Everolimus 64 Nymox NX 64 Brain Atrophy 64 Chronic Cough 64 Chronic lymphocytic leukemia 64 Pertuzumab 64 Endometrial 64 Recombinant Protein 64 Obstet Gynecol 64 Diabetic Retinopathy 64 Papillary 64 Effective Treatments 64 relapsing multiple sclerosis 64 Multicenter Phase 64 Enzastaurin 64 Ischaemic 64 Attenuates 64 Topline Results 64 Suicidality 64 Neoplasms 64 Contrast Agents 64 ST Elevation Myocardial 64 Oral Anticoagulant 64 Bipolar Depression 64 Apoptotic 64 Initiates Phase 64 Reduced Risk 64 Antiviral Drugs 64 Rare Genetic 64 Seasonal Influenza Vaccine 64 Trigeminal Neuralgia 64 Intravenous Formulation 64 Renal Artery 64 B Cell Malignancies 64 Physician Insights 64 Hematopoietic Stem Cell Transplantation 64 INSPIRE Trial Phase III 64 Gemcitabine 64 chronic granulomatous disease 64 Vaccine Adjuvant 64 Chronic Myeloid Leukemia CML 64 Tipranavir 64 Oral Presentation 64 Dapagliflozin 64 Stent Restenosis 64 Neuroprotection 64 Premature Birth 64 Hematopoietic 64 malignant pleural mesothelioma 64 Hepatocellular Carcinoma HCC 64 Therapeutic Vaccines 64 Taxane 64 Cancer Vaccine 64 BiTE Antibody 64 Imatinib 64 Prenatal Diagnosis 64 Bipolar Disorders 64 Adalimumab 63 Personalized Immunotherapy 63 Genetic Disorders 63 Recurrent Ovarian Cancer 63 Tocilizumab 63 Stent Thrombosis 63 Venous Thrombosis 63 Metastatic Cancer 63 Osteoporosis Drugs 63 Transdermal Patch 63 Therapy Shows Promise 63 dasatinib Sprycel 63 Cell Adhesion 63 Glatiramer Acetate 63 SNT-MC#/idebenone 63 Prednisone Against Refractory 63 Initiate Clinical Trial 63 Genetic Variations 63 Soy Isoflavones 63 Bone Marrow Cells 63 T#I [002] 63 Serious Infections 63 Ph + acute lymphoblastic 63 Immunogenicity 63 YONDELIS 63 Lymph Node 63 Reflux Disease 63 DNA Methylation 63 Cervical Dysplasia 63 Hepatitis C Patients 63 cell carcinoma RCC 63 Fibroblast 63 Parkinson Disease PD 63 Hedgehog Pathway 63 Vasomotor Symptoms 63 Poster Presentations 63 Ridaforolimus 63 Valvular Heart Disease 63 Paroxysmal Nocturnal Hemoglobinuria PNH 63 Eye Diseases 63 MRSA Infections 63 Treatment Outcome 63 Shown Effective 63 Cancer Immunotherapy 63 Expanded Indication 63 Minimally Invasive Treatment 63 Poster Discussion 63 Clinically Tested 63 Antiplatelet 63 Muscle Wasting 63 Temsirolimus 63 Stage IIB 63 Medullary Thyroid Cancer 63 Post Operative 63 Orthostatic Hypotension 63 Stem Cell Transplant 63 Peripheral Arterial 63 Progenitor Cell 63 receptor tyrosine kinase inhibitor 63 Peripheral Artery Disease 63 Valve Replacement 63 Introgen ADVEXIN 63 Oral Formulation 63 Arterial Disease 63 Chronic Liver Disease 63 Pivotal Phase II 63 Chemotherapy Improves 63 Mesothelioma Treatment 63 Cognitive Deficits 63 Glycosylation 63 galiximab 63 Smallpox Vaccine 63 Patients Enrolled 63 Menopausal Women 63 Telaprevir VX 63 Chemokine Receptor 63 Fabry Disease 63 Tezampanel 63 Efficacious 63 Erlotinib 63 Thyroid Disease 63 Ankylosing Spondylitis 63 GRNOPC1 contains 63 Fewer Side Effects 63 Antifungals 63 Bacterial Infection 63 Oncolytic 63 Gleevec resistant 63 Mg Usa 63 ASH Annual Meeting 63 dual endothelin receptor antagonist 63 Disease Modification 63 Metabolic Disease 63 Talabostat 63 Pulmonary Arterial Hypertension PAH 63 Presents Positive 63 Annamycin